HC Wainwright Has Bearish Estimate for GALT FY2027 Earnings

Galectin Therapeutics Inc. (NASDAQ:GALT) – Stock analysts at HC Wainwright dropped their FY2027 earnings estimates for shares of Galectin Therapeutics in a research note issued on Friday, November 15th. HC Wainwright analyst E. Arce now expects that the company will post earnings of $1.25 per share for the year, down from their prior forecast of $1.29. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ FY2028 earnings at $3.39 EPS.

Separately, StockNews.com cut shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th.

Galectin Therapeutics Stock Performance

Galectin Therapeutics stock opened at $2.77 on Monday. The stock has a market cap of $172.52 million, a P/E ratio of -3.79 and a beta of 0.62. Galectin Therapeutics has a fifty-two week low of $1.55 and a fifty-two week high of $4.27. The firm’s fifty day moving average price is $2.69 and its 200-day moving average price is $2.61.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Marshall Wace LLP bought a new position in shares of Galectin Therapeutics in the second quarter worth $43,000. Rhumbline Advisers purchased a new position in Galectin Therapeutics in the second quarter worth $44,000. Gladstone Institutional Advisory LLC purchased a new position in Galectin Therapeutics in the third quarter worth $60,000. Barclays PLC grew its position in Galectin Therapeutics by 309.0% in the third quarter. Barclays PLC now owns 28,587 shares of the company’s stock worth $79,000 after acquiring an additional 21,598 shares in the last quarter. Finally, Traynor Capital Management Inc. grew its position in Galectin Therapeutics by 23.5% in the second quarter. Traynor Capital Management Inc. now owns 42,871 shares of the company’s stock worth $97,000 after acquiring an additional 8,164 shares in the last quarter. Institutional investors own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.